Cargando…

OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance

BACKGROUND: Novel immunotherapeutic strategies, such as those targeting the PD-1/PD-L1 axis, are promising in patients with metastatic lung cancer and are often administered when tumors show PD-L1 positivity. The objective of this study was to analyze PD-L1 receptor discordance in tumor cell between...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonse, Raees, Rubens, Muni, Appel, Haley, Tom, Martin C, Hall, Matthew D, Odia, Yazmin, Mehta, Minesh P, McDermott, Michael W, Ahluwalia, Manmeet S, Kotecha, Rupesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351290/
http://dx.doi.org/10.1093/noajnl/vdab071.062
_version_ 1783735943668170752
author Tonse, Raees
Rubens, Muni
Appel, Haley
Tom, Martin C
Hall, Matthew D
Odia, Yazmin
Mehta, Minesh P
McDermott, Michael W
Ahluwalia, Manmeet S
Kotecha, Rupesh
author_facet Tonse, Raees
Rubens, Muni
Appel, Haley
Tom, Martin C
Hall, Matthew D
Odia, Yazmin
Mehta, Minesh P
McDermott, Michael W
Ahluwalia, Manmeet S
Kotecha, Rupesh
author_sort Tonse, Raees
collection PubMed
description BACKGROUND: Novel immunotherapeutic strategies, such as those targeting the PD-1/PD-L1 axis, are promising in patients with metastatic lung cancer and are often administered when tumors show PD-L1 positivity. The objective of this study was to analyze PD-L1 receptor discordance in tumor cell between the primary tumor and lung cancer brain metastasis (LCBM). METHODS: A systematic review of series published prior to April 2021 obtained from the Medline database of biopsied or resected LCBM evaluating PD-L1 discordance was performed using PRISMA guidelines. Weighted random effects models were used to calculate pooled estimates. RESULTS: Six full-text articles (n=247 patients) with a median of 32 patients in each study (range: 24–73 patients) reported PD-L1 receptor expression analyses of both primary lung tumors and brain metastases. The majority of patients (81%) were smokers, with 67% non-small cell lung cancer and 33% small cell lung cancer. The pooled estimate for overall PD-LI receptor concordance between primary and LCBM was 76% (95% CI: 52%-90). The positivity rate varied when analyzed by various cutoff levels of PD-L1 expression; for <1% expression, it was 41% (95% CI: 22%-62%) for primary vs. 58% (95% CI: 35%-78%) for LCBM; for PD-L1 expression of 1–50%, it was 24% (95% CI: 13%-40%) vs. 19% (95% CI: 10%-33%); and for PD-L1 >50% it was 12% (95% CI: 4%-33%) vs. 21% (95% CI: 14%-29%) (p=0.425). The pooled estimate for overall PD-LI receptor discordance between primary and LCBM was 17% (95% CI: 10%-27%). Meta-regression analysis showed that age, sex, smoking status, and histology were not associated with PD-LI receptor discordance. CONCLUSIONS: PD-L1 status discordance in tumor cell occurs in approximately 20% of LCBM, with the greatest discordance in the <1% expression category. Awareness of this discordance is important for the selection of immune checkpoint inhibitor therapy as well as in the analysis of patterns of failures.
format Online
Article
Text
id pubmed-8351290
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83512902021-08-09 OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance Tonse, Raees Rubens, Muni Appel, Haley Tom, Martin C Hall, Matthew D Odia, Yazmin Mehta, Minesh P McDermott, Michael W Ahluwalia, Manmeet S Kotecha, Rupesh Neurooncol Adv Supplement Abstracts BACKGROUND: Novel immunotherapeutic strategies, such as those targeting the PD-1/PD-L1 axis, are promising in patients with metastatic lung cancer and are often administered when tumors show PD-L1 positivity. The objective of this study was to analyze PD-L1 receptor discordance in tumor cell between the primary tumor and lung cancer brain metastasis (LCBM). METHODS: A systematic review of series published prior to April 2021 obtained from the Medline database of biopsied or resected LCBM evaluating PD-L1 discordance was performed using PRISMA guidelines. Weighted random effects models were used to calculate pooled estimates. RESULTS: Six full-text articles (n=247 patients) with a median of 32 patients in each study (range: 24–73 patients) reported PD-L1 receptor expression analyses of both primary lung tumors and brain metastases. The majority of patients (81%) were smokers, with 67% non-small cell lung cancer and 33% small cell lung cancer. The pooled estimate for overall PD-LI receptor concordance between primary and LCBM was 76% (95% CI: 52%-90). The positivity rate varied when analyzed by various cutoff levels of PD-L1 expression; for <1% expression, it was 41% (95% CI: 22%-62%) for primary vs. 58% (95% CI: 35%-78%) for LCBM; for PD-L1 expression of 1–50%, it was 24% (95% CI: 13%-40%) vs. 19% (95% CI: 10%-33%); and for PD-L1 >50% it was 12% (95% CI: 4%-33%) vs. 21% (95% CI: 14%-29%) (p=0.425). The pooled estimate for overall PD-LI receptor discordance between primary and LCBM was 17% (95% CI: 10%-27%). Meta-regression analysis showed that age, sex, smoking status, and histology were not associated with PD-LI receptor discordance. CONCLUSIONS: PD-L1 status discordance in tumor cell occurs in approximately 20% of LCBM, with the greatest discordance in the <1% expression category. Awareness of this discordance is important for the selection of immune checkpoint inhibitor therapy as well as in the analysis of patterns of failures. Oxford University Press 2021-08-09 /pmc/articles/PMC8351290/ http://dx.doi.org/10.1093/noajnl/vdab071.062 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Tonse, Raees
Rubens, Muni
Appel, Haley
Tom, Martin C
Hall, Matthew D
Odia, Yazmin
Mehta, Minesh P
McDermott, Michael W
Ahluwalia, Manmeet S
Kotecha, Rupesh
OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
title OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
title_full OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
title_fullStr OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
title_full_unstemmed OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
title_short OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance
title_sort othr-07. systematic review and meta-analysis of lung cancer brain metastasis and primary tumor pd-l1 expression discordance
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351290/
http://dx.doi.org/10.1093/noajnl/vdab071.062
work_keys_str_mv AT tonseraees othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT rubensmuni othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT appelhaley othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT tommartinc othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT hallmatthewd othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT odiayazmin othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT mehtamineshp othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT mcdermottmichaelw othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT ahluwaliamanmeets othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance
AT kotecharupesh othr07systematicreviewandmetaanalysisoflungcancerbrainmetastasisandprimarytumorpdl1expressiondiscordance